Caris Life Sciences Introduces Multimodal AI-Powered Molecular Insight to Identify the Benefit or Harm from the Addition of Chemotherapy for NSCLC Patients

Innovative AI-Driven Molecular Insight: Caris Life Sciences launched an AI-driven molecular insight for non-small cell lung cancer (NSCLC) patients to determine who may benefit from chemotherapy alongside immunotherapy.
Precision Oncology Advancements: The company applies its proprietary CodeAI™ platform to integrate multiple real-world datasets, enhancing precision oncology through comprehensive molecular profiling via sequencing technologies.
Improved Treatment Decisions: The new signature, developed from large-scale clinico-genomic datasets, identifies molecular signatures linked to treatment response, aiding personalized therapy choices for NSCLC patients.
Reduction in Unnecessary Chemotherapy: The AI model aims to help avoid subjects to chemotherapy that could be harmful, thereby improving patient care and outcomes in lung cancer treatment.
FDA-Approved Molecular Profiling Assay: Caris received FDA approval for MI Cancer Seek, the only simultaneous WES and WTS-based assay with companion diagnostic indications for solid tumor profiling.